Efficacy and Safety of Everolimus in de Novo Kidney Transplant Recipients of ECD or AKI Donors
Status:
Unknown status
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
Single center, open-label randomized-control trial Population: de novo 48 kidney transplant
recipients (age 18-75 years) from ECD/AKI donors Compare: everolimus with low dose CNI and
prednisolone versus standard immunosuppressive regimen Objective: To evaluate efficacy of
everolimus with low dose CNI in de novo kidney transplant recipients of ECD/AKI donors
Primary endpoint: Mean eGFR (CKD-EPI) at 12 months post-transplantation